In vivo detection of HER2-positive breast cancer and sentinel lymph node metastasis using activatable ICG-conjugated Trastuzumab

specificity. These results indicate the potential of Trastuzumab-ICG for high-specificity detection of HER2-positive breast cancer and its lymph node metastases, offering a promising tool for high-contrast tumor visualization and personalized treatment guidance.